Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
Background: Radiochemical purity is a key criterion for the quality of radiopharmaceuticals used in clinical practice. The joint improvement of analytical methods capable of identifying related radiochemical impurities and determining the actual radiochemical purity, as well as the improvement of sy...
Saved in:
| Main Authors: | Anton Larenkov, Iurii Mitrofanov, Marat Rakhimov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/12/1535 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: A case report
by: Yu-Yi Huang, et al.
Published: (2025-01-01) -
The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01) -
Theranostics Nuclear Medicine in Prostate Cancer
by: Helena Lima, et al.
Published: (2024-11-01) -
Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study
by: Sofía González-Rueda, et al.
Published: (2024-10-01) -
Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China
by: Fei Liu, et al.
Published: (2024-11-01)